Live attenuated vaccines against pertussis

Area of Science:

• Vaccinology
• Immunology
• Microbiology

Background:

• Pertussis (whooping cough) incidence decreased significantly due to 20th-century vaccines.
• Current acellular pertussis vaccines exhibit waning immunity and recent outbreaks highlight limitations.
• Natural infection induces robust, long-lasting immunity, serving as a model for improved vaccines.

Purpose of the Study:

• To describe the development of novel live attenuated pertussis vaccine candidates.
• To discuss the advantages of these new vaccines over existing pertussis vaccines.
• To explore potential anti-inflammatory applications beyond pertussis prevention.

Main Methods:

• Development of live attenuated vaccine candidates designed to mimic natural infection.
• Evaluation of vaccine efficacy and safety through preclinical and clinical trials (Phase I completed).
• Assessment of immunogenicity and potential "bystander" anti-inflammatory effects.

Main Results:

• A promising live attenuated pertussis vaccine candidate has successfully completed Phase I human trials.
• The developed vaccines aim to induce more durable immunity compared to current acellular vaccines.
• Preliminary findings suggest potential anti-inflammatory properties, broadening therapeutic scope.

Conclusions:

• Live attenuated pertussis vaccines represent a promising alternative to current regimens, potentially offering superior and longer-lasting protection.
• These novel vaccines may possess significant anti-inflammatory capabilities, expanding their therapeutic utility beyond infectious disease control.
• Further development and clinical trials are warranted to fully realize the potential of these advanced vaccine candidates.